Prognostic significance of inflammatory-related parameters in patients with anal canal cancer.
Anal carcinoma
Fibrinogen
Lymphocyte
Neutrophil
Radiotherapy
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
accepted:
21
12
2018
pubmed:
9
1
2019
medline:
26
7
2019
entrez:
9
1
2019
Statut:
ppublish
Résumé
To investigate the correlation between inflammatory-related parameters and overall survival (OS) and disease-free survival (DFS) in anal canal cancer population. Patients diagnosed with anal canal carcinoma and treated with curative intent chemoradiotherapy (CRT) were included. Data about pre-treatment complete blood count were collected. Neutrophil to lymphocyte ratio (NLR), fibrinogen (F), and a combination of these (F-NLR score) were correlated with OS. A total of 58 patients were enrolled. In multivariate analysis, the strongest OS prognostic factor was NLR, with a hazard ratio (HR) for low NLR compared to high NLR of 1.30 (95% confidence interval 1.01-14.12). Kaplan-Meier survival analysis showed that patients with high NLR, F, and F-NLR had significantly shorter OS and DFS. To our knowledge, this is the first study providing evidence that elevated pre-treatment NLR, F, and F-NLR score significantly correlate with worse survival outcomes in patients with anal canal carcinoma. In view of our findings, future clinical trials in anal canal cancer patients are warranted to verify our results.
Identifiants
pubmed: 30617412
doi: 10.1007/s00384-018-03225-7
pii: 10.1007/s00384-018-03225-7
doi:
Substances chimiques
Fibrinogen
9001-32-5
Types de publication
Journal Article
Langues
eng
Pagination
519-525Références
Acta Haematol. 1957 Apr;17(4):237-46
pubmed: 13434757
Colorectal Dis. 2014 Mar;16(3):O90-7
pubmed: 24148256
Radiat Oncol. 2014 Jan 28;9:39
pubmed: 24472223
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
BMJ Open. 2015 Apr 08;5(4):e006404
pubmed: 25854964
Int J Clin Exp Med. 2015 Mar 15;8(3):3098-106
pubmed: 26064198
Head Neck. 2016 Apr;38 Suppl 1:E1332-40
pubmed: 26362911
Medicine (Baltimore). 2015 Oct;94(40):e1670
pubmed: 26448011
Cancer Treat Rev. 2015 Dec;41(10):960-70
pubmed: 26604093
Oncology. 2016;90(4):186-92
pubmed: 26981856
Cancer Sci. 2017 Feb;108(2):193-199
pubmed: 27889946
Oncology. 2018;94(1):25-30
pubmed: 28918425
J Cell Physiol. 2018 May;233(5):4216-4224
pubmed: 29057536
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Int J Gynecol Cancer. 2018 Jun;28(5):939-944
pubmed: 29538251
Int J Biol Markers. 2018 Aug;33(3):254-265
pubmed: 29874984